Neuroprotective gene therapy in the aging brain

Aging is associated with a progressive increase in the incidence of neurodegenerative diseases in both laboratory animals and humans. In the central nervous system, cholinergic and dopaminergic (DA) neurons are among the cells most susceptible to the deleterious effects of age. Thus, the basal foreb...

Descripción completa

Detalles Bibliográficos
Autores principales: Pardo, Joaquín, Morel, Gustavo Ramón, Pereyra, Andrea Soledad, López León, Micaela, Brown, Oscar Alfredo, Bellini, María José, Goya, Rodolfo Gustavo, González Burgos, Ignacio
Formato: Libro Capitulo de libro
Lenguaje:Inglés
Publicado: Research Signpost 2014
Materias:
Ciencias Médicas
Envejecimiento
Enfermedad de Alzheimer
Terapia génica
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/151083
Aporte de:
SEDICI (UNLP) de Universidad Nacional de La Plata
id I19-R120-10915-151083
record_format dspace
spelling I19-R120-10915-1510832023-04-05T04:36:28Z http://sedici.unlp.edu.ar/handle/10915/151083 isbn:978-81-308-0550-4 Neuroprotective gene therapy in the aging brain Pardo, Joaquín Morel, Gustavo Ramón Pereyra, Andrea Soledad López León, Micaela Brown, Oscar Alfredo Bellini, María José Goya, Rodolfo Gustavo 2014 2023-04-04T17:13:11Z González Burgos, Ignacio Research Signpost en Ciencias Médicas Envejecimiento Enfermedad de Alzheimer Terapia génica Aging is associated with a progressive increase in the incidence of neurodegenerative diseases in both laboratory animals and humans. In the central nervous system, cholinergic and dopaminergic (DA) neurons are among the cells most susceptible to the deleterious effects of age. Thus, the basal forebrain cholinergic system is known to undergo moderate neurodegenerative changes during normal aging as well as severe atrophy in Alzheimer’s disease (AD). Parkinson's disease (PD), a degeneration of nigro-striatal DA neurons is the most conspicuous reflection of the vulnerability of DA neurons to age. Overall, there is growing evidence that a progressive decline in cognitive function and central DA activity represents basic features of normal aging both in humans and laboratory rodents. Exacerbation of these processes contributes to the symptoms of AD and PD, respectively. In this context, neurotrophic factors that can prevent or delay the decline in cognitive function and central DA activity during normal aging may reveal new therapeutic avenues for treatment of AD and PD and are therefore of clinical interest. Among the peptide factors, Insulin-like Growth Factor I (IGF-I) and Glial cell line-Derived Neurotrophic Factor are emerging as powerful neuroprotective molecules for the treatment of neurodegenerative pathologies. Among the neurosteroids, estrogens are recognized as neuroprotective and seem to act synergistically with IGF-I and possibly other neurotrophic peptides. This chapter will discuss the evidence supporting the neuroprotective relevance of the above factors. Instituto de Investigaciones Bioquímicas de La Plata Libro Capitulo de libro http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) application/pdf
institution Universidad Nacional de La Plata
institution_str I-19
repository_str R-120
collection SEDICI (UNLP)
language Inglés
topic Ciencias Médicas
Envejecimiento
Enfermedad de Alzheimer
Terapia génica
spellingShingle Ciencias Médicas
Envejecimiento
Enfermedad de Alzheimer
Terapia génica
Pardo, Joaquín
Morel, Gustavo Ramón
Pereyra, Andrea Soledad
López León, Micaela
Brown, Oscar Alfredo
Bellini, María José
Goya, Rodolfo Gustavo
González Burgos, Ignacio
Neuroprotective gene therapy in the aging brain
topic_facet Ciencias Médicas
Envejecimiento
Enfermedad de Alzheimer
Terapia génica
description Aging is associated with a progressive increase in the incidence of neurodegenerative diseases in both laboratory animals and humans. In the central nervous system, cholinergic and dopaminergic (DA) neurons are among the cells most susceptible to the deleterious effects of age. Thus, the basal forebrain cholinergic system is known to undergo moderate neurodegenerative changes during normal aging as well as severe atrophy in Alzheimer’s disease (AD). Parkinson's disease (PD), a degeneration of nigro-striatal DA neurons is the most conspicuous reflection of the vulnerability of DA neurons to age. Overall, there is growing evidence that a progressive decline in cognitive function and central DA activity represents basic features of normal aging both in humans and laboratory rodents. Exacerbation of these processes contributes to the symptoms of AD and PD, respectively. In this context, neurotrophic factors that can prevent or delay the decline in cognitive function and central DA activity during normal aging may reveal new therapeutic avenues for treatment of AD and PD and are therefore of clinical interest. Among the peptide factors, Insulin-like Growth Factor I (IGF-I) and Glial cell line-Derived Neurotrophic Factor are emerging as powerful neuroprotective molecules for the treatment of neurodegenerative pathologies. Among the neurosteroids, estrogens are recognized as neuroprotective and seem to act synergistically with IGF-I and possibly other neurotrophic peptides. This chapter will discuss the evidence supporting the neuroprotective relevance of the above factors.
format Libro
Capitulo de libro
author Pardo, Joaquín
Morel, Gustavo Ramón
Pereyra, Andrea Soledad
López León, Micaela
Brown, Oscar Alfredo
Bellini, María José
Goya, Rodolfo Gustavo
González Burgos, Ignacio
author_facet Pardo, Joaquín
Morel, Gustavo Ramón
Pereyra, Andrea Soledad
López León, Micaela
Brown, Oscar Alfredo
Bellini, María José
Goya, Rodolfo Gustavo
González Burgos, Ignacio
author_sort Pardo, Joaquín
title Neuroprotective gene therapy in the aging brain
title_short Neuroprotective gene therapy in the aging brain
title_full Neuroprotective gene therapy in the aging brain
title_fullStr Neuroprotective gene therapy in the aging brain
title_full_unstemmed Neuroprotective gene therapy in the aging brain
title_sort neuroprotective gene therapy in the aging brain
publisher Research Signpost
publishDate 2014
url http://sedici.unlp.edu.ar/handle/10915/151083
work_keys_str_mv AT pardojoaquin neuroprotectivegenetherapyintheagingbrain
AT morelgustavoramon neuroprotectivegenetherapyintheagingbrain
AT pereyraandreasoledad neuroprotectivegenetherapyintheagingbrain
AT lopezleonmicaela neuroprotectivegenetherapyintheagingbrain
AT brownoscaralfredo neuroprotectivegenetherapyintheagingbrain
AT bellinimariajose neuroprotectivegenetherapyintheagingbrain
AT goyarodolfogustavo neuroprotectivegenetherapyintheagingbrain
AT gonzalezburgosignacio neuroprotectivegenetherapyintheagingbrain
_version_ 1765659903654887424

Ejemplares similares